Janus kinase (JAK)
Showing 1 - 25 of 2,287
Janus Kinase Inhibitors Vs Tumor Necrosis Factor Inhibitors in
Not yet recruiting
- Rheumatoid Arthritis
- Observation
- (no location specified)
Oct 8, 2022
Diabetes, Type 1 Trial (Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo)
Not yet recruiting
- Diabetes Mellitus, Type 1
- Abrocitinib 200 MG Oral Tablet
- +2 more
- (no location specified)
Feb 21, 2023
Abatacept, Treatment Compliance, Rheumatoid Arthritis Trial in Hangzhou (Janus Kinase Inhibitor, Abatacept)
Recruiting
- Abatacept
- +2 more
- Janus Kinase Inhibitor
- Abatacept
-
Hangzhou, Zhejiang, ChinaZhejiang Provincial People's Hospital
Jul 5, 2022
Alopecia Areata Trial in Sohag (Janus Kinase 1 and 2)
Recruiting
- Alopecia Areata
- Janus Kinase 1 and 2
-
Sohag, EgyptSohag University hospitals
May 12, 2023
Sarcoidosis Trial in New Haven (Abrocitinib 200 mg)
Not yet recruiting
- Sarcoidosis
- Abrocitinib 200 mg
-
New Haven, ConnecticutYale University
Jan 24, 2023
Granuloma Annulare Trial in New Haven (Abrocitinib 200 mg)
Not yet recruiting
- Granuloma Annulare
- Abrocitinib 200 mg
-
New Haven, ConnecticutYale University
Dec 19, 2022
Myelofibrosis Trial in Worldwide (Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg)
Completed
- Myelofibrosis
- Imetelstat 4.7 mg/kg
- Imetelstat 9.4 mg/kg
-
Birmingham, Alabama
- +71 more
Aug 17, 2021
Sjogren's Syndrome Trial run by the National Institute of Dental and Craniofacial Research (NIDCR) (tofacitinib, Placebo)
Recruiting
- Sjogren's Syndrome
- tofacitinib
- Placebo
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Nov 24, 2022
Janus Kinase Inhibitor Therapy in Ulcerative Colitis
Terminated
- Ulcerative Colitis
- Janus Kinase Inhibitor
-
Amsterdam, North Halland, NetherlandsAmsterdam Medical Center, IBD Center
Dec 14, 2021
Idiopathic Inflammatory Myopathies Trial in Beijing (tofacitinib)
Recruiting
- Idiopathic Inflammatory Myopathies
-
Beijing, Beijing, ChinaDepartment of Rheumatology and Immunology, Peking University Peo
Oct 9, 2022
Lupus or SLE, Nephritis Trial in Assiut (Baricitinib 4 MG, Baricitinib 2 MG, MMF)
Recruiting
- Lupus or SLE
- Nephritis
- Baricitinib 4 MG
- +2 more
-
Assiut, Yes, EgyptManal Hassanien
Jan 13, 2023
Chronic Kidney Diseases Trial in Durham (Baricitinib, Placebo)
Recruiting
- Chronic Kidney Diseases
- Baricitinib
- Placebo
-
Durham, North CarolinaDuke Research at Pickett Road
Dec 15, 2022
Myelofibrosis Trial in Worldwide (Imetelstat, Best Available Therapy (BAT))
Recruiting
- Myelofibrosis
- Imetelstat
- Best Available Therapy (BAT)
-
La Jolla, California
- +165 more
Aug 19, 2022
Lupus Nephritis Trial in Assiut (Anti JAK1,2)
Active, not recruiting
- Lupus Nephritis
- Anti JAK1,2
-
Assiut, Assuit, EgyptManal Hassanien
Jun 21, 2022
JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
Not yet recruiting
- Pyoderma Gangrenosum
- +2 more
- immunohistochemical methods
- (no location specified)
Mar 21, 2022
Rheumatoid Arthritis Trial in London (Etanercept, tofacitinib)
Recruiting
- Rheumatoid Arthritis
-
London, Ontario, CanadaRheumatology Clinic, St. Joseph's Health Care
May 10, 2022
JAK Inhibition in Ulcerative Colitis
Not yet recruiting
- Analyzing Immune Composition Changes Upon JAK Inhibitor Treatment of Ulcerative Colitis Patients
- JAK inhibitor treatment
- (no location specified)
Jul 11, 2022
Acneiform Eruptions Trial in Shanghai (Cream containing JAK Inhibitor)
Recruiting
- Acneiform Eruptions
- Cream containing JAK Inhibitor
-
Shanghai, Shanghai, ChinaShanghai East Hospital
Jun 20, 2022
COVID-19 Trial in Halifax (Baricitinib (janus kinase inhibitor), Remdesivir (antiviral) + barictinib (janus kinase inhibitor),
Recruiting
- COVID-19
- Baricitinib (janus kinase inhibitor)
- +3 more
-
Halifax, Nova Scotia, CanadaNova Scotia Health Authority
Mar 9, 2022
Cutaneous Sarcoidosis, Granuloma Annulare Trial in New Haven (Tofacitinib 5 mg twice daily)
Completed
- Cutaneous Sarcoidosis
- Granuloma Annulare
- Tofacitinib 5 mg twice daily
-
New Haven, ConnecticutYale Center for Clinical Investigation
Jul 13, 2021
Inpatient COVID-19 Treatments
Active, not recruiting
- COVID-19
- Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)
-
New York, New YorkAetion, Inc.
Jan 12, 2023
Non-sclerotic Cutaneous Chronic Graft-versus-host Disease Trial in New York (topical ruxolitinib 1.5% cream, Topical
Recruiting
- Non-sclerotic Cutaneous Chronic Graft-versus-host Disease
- topical ruxolitinib 1.5% cream
- Topical vehicle/moisturizer cream
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Dec 20, 2022